Insulin resistance, fluctuations in hormones, irregular ovulation, and metabolic health can all have a significant effect on fertility in women with polycystic ovarian syndrome (PCOS). As a result, a growing interest in glucagon-like peptide-1 (GLP-1) medications and polycystic ovarian syndrome (PCOS) has increased, mainly as medications such as semaglutide and liraglutide become increasingly considered for metabolic health and for management of weight.
But can glucagon-like peptide-1 (GLP-1) medications improve fertility in women with polycystic ovarian syndrome (PCOS)? Although not simple, the answer is promising. In some women, these medications may indirectly support reproductive health, but they are not a proven method for the treatment of fertility.
What Is PCOS and How Can It Affect Fertility?
Polycystic ovarian syndrome (PCOS) is a common hormonal and metabolic condition that can affect ovulation and menstrual cycles. Women with polycystic ovarian syndrome may experience irregular periods, insulin resistance, acne, or excess hair growth, and increased androgen levels.
Why Does PCOS Affect Ovulation?
Due to insulin resistance, the increased insulin levels may have an impact on the production of ovarian hormones. Regular ovulation can be affected due to this hormonal imbalance. The chance of conception may decrease if ovulation is less frequent. However, having polycystic ovarian syndrome (PCOS) does not indicate that a woman cannot become pregnant. Most women with polycystic ovarian syndrome conceive naturally or with the proper fertility treatment.
How Do GLP-1 Medications Work?
Glucagon-like peptide-1 (GLP-1) receptor agonists have similar functions to the naturally occurring hormone called glucagon-like peptide-1. Depending on the medication, they may help to regulate the blood glucose level, reduce hunger, slow stomach emptying, and support weight loss.
Examples of drugs include semaglutide, liraglutide, and tirzepatide. As their approved uses differ, they should only be used as per the advice of healthcare professionals.
As metabolic health and reproductive health are closely connected, the relationship between GLP-1 drugs and polycystic ovarian syndrome (PCOS) is particularly important.
Can GLP-1 Medications Improve Fertility in PCOS?
According to research, glucagon-like peptide-1 (GLP-1) drugs may be beneficial for reproduction, mainly for women with polycystic ovarian syndrome (PCOS) who are also overweight or dealing with obesity.
In some women, improved insulin sensitivity and weight loss may help to restore more regular menstrual cycles and ovulation. According to the systematic review and meta-analysis, glucagon-like peptide (GLP-1) receptor agonists may increase menstrual regularity and natural pregnancy rates in women with polycystic ovarian syndrome. However, the evidence is still limited and further study is required.
Do GLP-1 Drugs Directly Increase Fertility?
Not necessarily.
GLP-1 drugs may not directly increase fertility, but rather they increase metabolic health, insulin resistance, and body weight.
This difference is very important. GLP-1 drugs should not be used as a substitute of evidence-based reproductive treatments.
Fertility also depends on the age, sperm health, ovarian reserve, function of fallopian-tube and other reproductive factors.
GLP-1 Medications and Pregnancy: What Should Women Know?
Women who are trying to conceive should discuss GLP-1 medication with their healthcare professionals.
Generally, these drugs are not recommended for use during pregnancy, and recommendations about stopping the treatment before conception may vary depending on the specified medication. For example, because of semaglutide's prolonged presence in the body, the prescribing information advises stopping the medication at least two months before a planned pregnancy.
What If Pregnancy Occurs While Taking a GLP-1 Medication?
If pregnancy occurs while using a GLP-1 drug, immediately contact the prescribing healthcare professional. Without medical advice, do not continue or discontinue the prescription treatment independently.
What Are the Fertility Treatment Options for PCOS?
For women with polycystic ovarian syndrome (PCOS) who are struggling to conceive, healthcare professionals can evaluate ovulation, metabolic health, and other potential fertility factors.
Depending on the specific conditions, treatment options may include ovulation-inducing medication, lifestyle interventions, or assisted reproductive techniques.
The objective is not simply to reduce weight but to address the factors that may be preventing regular ovulation and conception.
Conclusion
Research on the relationship between GLP-1 medications and PCOS is still in progress. By reducing excess weight, improving metabolic factors, and potentially increasing ovulation in some women, these drugs may indirectly promote reproductive health.
Though they are not yet fertility medications, more thorough research is required to determine their long-term advantages and disadvantages for reproduction.
If you have polycystic ovarian syndrome (PCOS) and are planning for pregnancy, talk to a gynecologist or other qualified healthcare professionals before starting, stopping, or continuing a GLP-1 medication.
References
- American College of Obstetricians and Gynecologists. Polycystic Ovary Syndrome (PCOS). ACOG.
- Teede HJ, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Human Reproduction. 2023;38(9):1655–1671.
- Jensterle M, et al. Metabolic effects of GLP-1 receptor agonists in women with polycystic ovary syndrome. Journal of Clinical Endocrinology & Metabolism.
- U.S. Food and Drug Administration. Wegovy (semaglutide) Prescribing Information. FDA.
- Jensterle M, et al. Use of GLP-1 receptor agonists in the management of polycystic ovary syndrome: emerging evidence and future perspectives. Endocrine Connections.
